In this week’s issue of JAMA Oncology, there is an important paper that provides information concerning the long-term adverse effects and complications of prostate cancer screening and treatment.1
Exact Sciences Corp. announced the launch of Cologuard Plus, the most accurate noninvasive colorectal cancer screening test reported in studies to date. FDA-approved for average-risk patients 45+ and covered by Medicare, the Cologuard Plus test detects 95% of colorectal cancers at 94% specificity in the U.S. screening population.
